Title

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry

Authors

P. J. Mease, University of Washington
J. B. Palmer, Novartis Pharmaceuticals Corporation
P. Hur, Novartis Pharmaceuticals Corporation
B. E. Strober, University of Connecticut Health Center
M. Lebwohl, Icahn School of Medicine at Mount Sinai
C. Karki, Corrona, LLC
G. W. Reed, George.Reed@umassmed.edu
C. J. Etzel, Corrona, LLC
J. D. Greenberg, New York University
P. S. Helliwell, University of Leeds

UMMS Affiliation

Division of Preventive and Behavioral Medicine

Publication Date

2019-05-01

Document Type

Article

Disciplines

Dermatology | Diagnosis | Epidemiology | Musculoskeletal Diseases | Skin and Connective Tissue Diseases

Abstract

BACKGROUND: Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a five-item questionnaire developed to help identify PsA at an early stage.

OBJECTIVES: To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores.

METHODS: This study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient-reported outcomes were compared in Corrona PsO Registry patients with PEST scores > /=3 and < 3 using t-tests for continuous variables and chi-squared tests for categorical variables; scores > /=3 may indicate PsA.

RESULTS: Of 1516 patients with PsO, 904 did not have dermatologist-reported PsA; 112 of these 904 patients (12.4%) scored > /=3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores < 3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment.

CONCLUSIONS: Improved PsA screening is needed in patients with PsO because the validated PEST identified over one-tenth of registry patients who were not noted to have PsA as having scores > /=3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health-related quality of life and worse activity impairment.

Rights and Permissions

© 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI of Published Version

10.1111/jdv.15443

Source

J Eur Acad Dermatol Venereol. 2019 May;33(5):886-892. doi: 10.1111/jdv.15443. Epub 2019 Mar 5. Link to article on publisher's site

Journal/Book/Conference Title

Journal of the European Academy of Dermatology and Venereology : JEADV

Related Resources

Link to Article in PubMed

PubMed ID

30663130

Repository Citation

Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS. (2019). Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Open Access Publications by UMass Chan Authors. https://doi.org/10.1111/jdv.15443. Retrieved from https://escholarship.umassmed.edu/oapubs/3795

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License